dimethyl syn-5-hydroxycyclohexane-cis-1,3-dicarboxylate | 38859-08-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: dimethyl syn-5-hydroxycyclohexane-cis-1,3-dicarboxylate
• CAS: 38859-08-4
• 化学式: C₁₀H₁₆O₅
• 分子量: 216.234
• InChiKey: WINOVBXKECSWMZ-RNLVFQAGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.11
• 重原子数：
  15.0
• 可旋转键数：
  2.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  72.83
• 氢给体数：
  1.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  dimethyl syn-5-hydroxycyclohexane-cis-1,3-dicarboxylate 在 草酰氯 、 二乙胺基三氟化硫 、 二甲基亚砜 、 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 、 1,2-二氯乙烷 为溶剂， 反应 7.0h， 生成 7,7-difluoro-3-oxabicyclo[3.3.1]nonane-2,4-dione
  参考文献：
  名称：

  [EN] PLATELET-ACTIVATING FACTOR RECEPTOR ANTAGONISTS
  [FR] ANTAGONISTES DES RÉCEPTEURS DU FACTEUR D'ACTIVATION PLAQUETTAIRE

  摘要：

  环己基磺胺化合物是血小板活化因子（PAF）受体拮抗剂。这些化合物可能对治疗动脉粥样硬化或其他PAF介导的疾病有用，包括炎症性、心血管和免疫性疾病。

  公开号：

  WO2011005608A1
• 作为产物：
  描述：

  5-羟基间苯二甲酸二甲酯 在 Rh/Al₂O₃ 氢气 作用下， 以 甲醇 为溶剂， 反应 72.0h， 生成 dimethyl syn-5-hydroxycyclohexane-cis-1,3-dicarboxylate
  参考文献：
  名称：

  [EN] PLATELET-ACTIVATING FACTOR RECEPTOR ANTAGONISTS
  [FR] ANTAGONISTES DES RÉCEPTEURS DU FACTEUR D'ACTIVATION PLAQUETTAIRE

  摘要：

  环己基磺胺化合物是血小板活化因子（PAF）受体拮抗剂。这些化合物可能对治疗动脉粥样硬化或其他PAF介导的疾病有用，包括炎症性、心血管和免疫性疾病。

  公开号：

  WO2011005608A1

文献信息

• MONOMER, POLYMER, RESIST COMPOSITION, AND PATTERNING PROCESS
  申请人：Shin-Etsu Chemical Co., Ltd.

  公开号：US20160179002A1

  公开（公告）日：2016-06-23

  A monomer having a plurality of tertiary alcoholic hydroxyl groups is provided. A useful polymer is obtained by polymerizing the monomer. From a resist composition comprising the polymer, a negative pattern which is insoluble in alkaline developer and has high etch resistance is formed at a high resolution.

  提供一种具有多个三级醇羟基的单体。通过聚合这种单体可以获得一种有用的聚合物。从包含该聚合物的抗蚀组合物中，可以形成一种在高分辨率下不溶于碱性显影剂且具有高蚀刻抵抗力的负图案。
• PLATELET-ACTIVATING FACTOR RECEPTOR ANTAGONISTS
  申请人：Ogawa Anthony

  公开号：US20120108595A1

  公开（公告）日：2012-05-03

  Cyclohexyl sulfonamide compounds which are platelet-activating factor (PAF) receptor antagonists. Said compounds may be useful, for example, for the treatment of atherosclerosis or other PAF-mediated disorders, including inflammatory, cardiovascular, and immune disorders.

  环己基磺酰胺化合物是血小板活化因子(PAF)受体拮抗剂。该化合物可能有用，例如，用于治疗动脉粥样硬化或其他PAF介导的疾病，包括炎症，心血管和免疫疾病。
• Inositol compounds and uses of same in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, desposition, accumulation or persistence
  申请人：Cruz Antonio

  公开号：US20070111970A1

  公开（公告）日：2007-05-17

  Inositol derivatives are described that are represented by the structural formula I wherein X is a radical of scyllo-inositol wherein one or more of R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are independently alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, cycloalkoxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, sulfoxide, sulfate, sulfonyl, sulfenyl, sulfonate, sulfinyl, amino, imino, azido, thiol, thioalkyl, thioalkoxy, thioaryl, nitro, cyano, halo, seleno, silyl, silyloxy, silylthio, carboxyl, carbonyl, carbamoyl, or carboxamide and the other of R 1 , R 2 , R 3 , R 4 , R 5 , or R 6 are hydroxyl, or pharmaceutically acceptable salts thereof. The compounds, compositions comprising same and methods using same are described for use in the prevention and/or treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, desposition, accumulation or persistence.
• SCYLLO-INOSITOL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASES CHARACTERIZED BY ABNORMAL PROTEIN FOLDING OR AGGREGATION OR AMYLOID FORMATION, DEPOSITION, ACCUMULATION OR PERSISTENCE
  申请人：Cruz Antonio

  公开号：US20090170957A1

  公开（公告）日：2009-07-02

  Scyllo-Inositol derivatives represented by structural formula II are described, wherein at least one and not more than five of R 1 , R 2 , R 3 , R 4 , R 5 and R 6 is hydroxyl and the other of R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are independently alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, cycloalkoxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, sulfoxide, sulfate, sulfonyl, sulfenyl, sulfonate, sulfinyl, ammo, lmmo, azido, thiol, thioalkyl, thioaryl, mtro, cyano, halo, seleno, silyl, silyloxy, silylthio, carboxyl, carbonyl, carbamoyl or carbamide, or pharmaceutically acceptable salts thereof. Said derivatives and compositions comprising the same are useful in the prevention and/or treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, deposition, accumulation or persistence.
• Inositol Compounds and Uses of Same in the Treatment of Diseases Characterized by Abnormal Protein Folding or Aggregation or Amyloid Formation, Desposition, Accumulation or Persistence
  申请人：Curz Antonio

  公开号：US20100105631A1

  公开（公告）日：2010-04-29

  Inositol derivatives are described that are represented by the structural formula I wherein X is a radical of scyllo-inositol wherein one or more of R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are independently alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, cycloalkoxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, sulfoxide, sulfate, sulfonyl, sulfenyl, sulfonate, sulfinyl, amino, imino, azido, thiol, thioalkyl, thioalkoxy, thioaryl, nitro, cyano, halo, seleno, silyl, silyloxy, silylthio, carboxyl, carbonyl, carbamoyl, or carboxamide and the other of R 1 , R 2 , R 3 , R 4 , R 5 , or R 6 are hydroxyl, or pharmaceutically acceptable salts thereof. The compounds, compositions comprising same and methods using same are described for use in the prevention and/or treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, desposition, accumulation or persistence.